{'fraction_non_alphanumeric': 0.037489812550937245, 'fraction_numerical': 0.03341483292583537, 'mean_word_length': 4.903846153846154, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Anti-Toxoplasma gondii activity of curcumin: A systematic review of pre-clinical studies.

OBJECTIVE
This study is about anti-Toxoplasma gondii activity of curcumin: a systematic review of pre-clinical studies.


METHODS
In this systematic review, anti-parasitic activity of Curcuma longa on Toxoplasma gondii was assessed. Therefore, several databases, including PubMed, Scopus, Web of Science, Embase and Google Scholar were searched from 2010 to 2020.


RESULTS
Of the 2200 papers retrieved between 2010 and 2020, six articles were reliable and were scrutinized. From 2 in vitro studies, the most used strain was RH strain of Toxoplasma gondii, whereas among 4 in vivo studies, RH strain with 2 (50%) studies, Me49 strain with 1(25%) study, RH and Me49 strain with 1(25%) studies, From four in vivo studies, the most used animal model was BALB/c, and Swiss albino with 1 study (25%) and Albino rats with 1 study (25%).


CONCLUSION
The combination of curcumin and nanoparticles formulated with curcumin are new and useful agents for the treatment of parasitic diseases and reduction of drug resistance. The success of this therapeutic approach stems from the specific action of Curcuma longa against parasites and pathogens.